Oxford BioMedica PLC Market Cap ($8.02 Million)
Market Cap & Net Worth: Oxford BioMedica PLC (OXB)
Oxford BioMedica PLC market cap. Oxford BioMedica PLC (LSE:OXB) has a market capitalization of $8.02 Million (GBX65.93 Billion) as of November 8, 2026. Listed on the LSE stock exchange, this UK-based company holds position #27446 globally and #388 in its home market, demonstrating a 2.63% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Oxford BioMedica PLC's stock price GBX546.00 by its total outstanding shares 120751662 (120.75 Million). Also see Oxford BioMedica PLC cash conversion from operations for how efficiently the company converts equity into cash flow.
Oxford BioMedica PLC Market Cap History (2015–2026)
Oxford BioMedica PLC market cap history from 2015 to 2026. Data shows growth from $4.77 Million to $8.02 Million (3.47% CAGR). Check latest Oxford BioMedica PLC stock price today for real-time trading data and today's change.
Index Memberships
Oxford BioMedica PLC is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
FTSE All-Share
FTAS
|
$67.98 Billion | 0.01% | #288 of 573 |
Weight: Oxford BioMedica PLC's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Oxford BioMedica PLC Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Oxford BioMedica PLC's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Oxford BioMedica PLC (OXB) equity growth momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.05x
Oxford BioMedica PLC's market cap is 0.05 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $4.77 Million | $15.91 Million | -$13.02 Million | 0.30x | N/A |
| 2016 | $2.99 Million | $27.78 Million | -$16.64 Million | 0.11x | N/A |
| 2017 | $6.50 Million | $37.59 Million | -$9.02 Million | 0.17x | N/A |
| 2018 | $10.39 Million | $66.78 Million | $7.54 Million | 0.16x | 1.38x |
| 2019 | $9.48 Million | $64.06 Million | -$16.07 Million | 0.15x | N/A |
| 2020 | $15.13 Million | $87.73 Million | -$6.25 Million | 0.17x | N/A |
| 2021 | $18.07 Million | $142.80 Million | $19.01 Million | 0.13x | 0.95x |
| 2022 | $6.50 Million | $139.99 Million | -$39.16 Million | 0.05x | N/A |
| 2023 | $3.23 Million | $89.54 Million | -$157.49 Million | 0.04x | N/A |
| 2024 | $6.17 Million | $128.80 Million | -$43.19 Million | 0.05x | N/A |
Competitor Companies of OXB by Market Capitalization
Companies near Oxford BioMedica PLC in the global market cap rankings as of November 8, 2026. Also see total assets of Oxford BioMedica PLC for a full breakdown of the balance sheet.
Key companies related to Oxford BioMedica PLC by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #177 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #363 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #403 globally with a market cap of $69.36 Billion USD ( AU$98.02 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #177 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $547.09 |
| #363 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $904.35 |
| #403 | CSL Ltd | AU:CSL | $69.36 Billion | AU$202.04 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $254.19 |
Market Capitalization of Oxford BioMedica PLC (2015–2026)
Market capitalization of Oxford BioMedica PLC from 2015 to today. Between 2015 and today, Oxford BioMedica PLC's market cap moved from $4.77 Million to $ 8.02 Million, with a yearly change of 3.47%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | GBX8.02 Million | -11.51% |
| 2025 | GBX9.06 Million | +46.90% |
| 2024 | GBX6.17 Million | +90.91% |
| 2023 | GBX3.23 Million | -50.28% |
| 2022 | GBX6.50 Million | -64.02% |
| 2021 | GBX18.07 Million | +19.42% |
| 2020 | GBX15.13 Million | +59.69% |
| 2019 | GBX9.48 Million | -8.80% |
| 2018 | GBX10.39 Million | +59.82% |
| 2017 | GBX6.50 Million | +117.44% |
| 2016 | GBX2.99 Million | -37.38% |
| 2015 | GBX4.77 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 7th, 2026 the market cap of Oxford BioMedica PLC was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $8.02 Million USD |
| MoneyControl | $8.02 Million USD |
| MarketWatch | $8.02 Million USD |
| marketcap.company | $8.02 Million USD |
| Reuters | $8.02 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Oxford BioMedica PLC
Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its LentiVector platform technology is a lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The… Read more